MODULATION THERAPEUTICS, INC.

Basic Information

2711 CENTERVILLE RD, STE 400
WILMINGTON, DE, 19808-0000

http://modulationtherapeutics.com/default.html

Company Profile

Modulation Therapeutics Incorporated is a research and development pharmaceutical company.

Additional Details

Field Value
DUNS: 968675244
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 6


  1. IGF OT IGF SBIR TOPIC

    Amount: $299,336.00

    Not Available

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  2. Targeting CD137L to MC1R-Expressing Melanoma Cells and Tumors.

    Amount: $244,801.00

    DESCRIPTION provided by applicant There are specific high affinity ligands for receptors found on many cancers that have been investigated as imaging probes and we believe that we should try to enh ...

    STTR Phase I 2015 Department of Health and Human Services National Institutes of Health
  3. Second generation MTI-101 analogs using a novel peptoid-peptide hybrid beta-hairp

    Amount: $225,000.00

    MTI-101 is a cyclic beta-hairpin peptide that binds CD44 with high affinity and kills multiple myeloma cell lines in vitro and blocks the growth of myeloma tumors in 2 different murine models. This in ...

    STTR Phase I 2014 Department of Health and Human Services
  4. A Virtually Supervised Web-Based Home Exercise Technology for Older Adults

    Amount: $288,301.00

    DESCRIPTION (provided by applicant): The majority of multiple myeloma (MM) patients will initially respond to standard chemotherapy. However, eventually relapse of the disease, associated with a multi ...

    SBIR Phase I 2013 Department of Health and Human Services
  5. Chemical Optimization Designed to Increase the in vivo Efficacy of HM-27 for the

    Amount: $156,202.00

    DESCRIPTION (provided by applicant): This application requests funds to aid in obtaining the necessary additional preclinical data needed for commercialization of a promising new and novel drug candid ...

    SBIR Phase I 2012 Department of Health and Human Services
  6. Targeting CD44 in the bone marrow microenvironment of MM

    Amount: $218,817.00

    DESCRIPTION (provided by applicant): The majority of multiple myeloma (MM) patients will initially respond to standard chemotherapy. However, eventually relapse of the disease, associated with a multi ...

    SBIR Phase I 2012 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government